Coronary artery disease (CAD) remains one of the most important causes of morbidity and mortality worldwide, and revascularization through percutaneous coronary interventions (PCI) significantly improves survival. In this setting, poor glycaemic control, regardless of diabetes, has been associated with increased incidence of peri-procedural and long-term complications and worse prognosis. Novel antidiabetic agents have represented a paradigm shift in managing patients with diabetes and cardiovascular diseases. However, limited data are reported so far in patients undergoing coronary stenting. This review intends to provide an overview of the biological mechanisms underlying hyperglycaemia-induced vascular damage and the contrasting actions of new antidiabetic drugs. We summarize existing evidence on the effects of these drugs in the setting of PCI, addressing pre-clinical and clinical studies and drug-drug interactions with antiplatelet agents, thus highlighting new opportunities for optimal long-term management of these patients.

Nusca, A., Piccirillo, F., Bernardini, F., Filippis, A.d., Coletti, F., Mangiacapra, F., et al. (2022). Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(13), 7261 [10.3390/ijms23137261].

Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data

Bernardini F.;Cammalleri V.;Ussia G. P.;
2022

Abstract

Coronary artery disease (CAD) remains one of the most important causes of morbidity and mortality worldwide, and revascularization through percutaneous coronary interventions (PCI) significantly improves survival. In this setting, poor glycaemic control, regardless of diabetes, has been associated with increased incidence of peri-procedural and long-term complications and worse prognosis. Novel antidiabetic agents have represented a paradigm shift in managing patients with diabetes and cardiovascular diseases. However, limited data are reported so far in patients undergoing coronary stenting. This review intends to provide an overview of the biological mechanisms underlying hyperglycaemia-induced vascular damage and the contrasting actions of new antidiabetic drugs. We summarize existing evidence on the effects of these drugs in the setting of PCI, addressing pre-clinical and clinical studies and drug-drug interactions with antiplatelet agents, thus highlighting new opportunities for optimal long-term management of these patients.
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/11
English
anti-diabetic agents
coronary artery disease
coronary stenting
diabetes mellitus
glycaemic control
glycaemic variability
hyperglycaemia
percutaneous coronary intervention
Glycemic Control
Humans
Hypoglycemic Agents
Risk Factors
Treatment Outcome
Coronary Artery Disease
Diabetes Mellitus
Hyperglycemia
Percutaneous Coronary Intervention
Nusca, A., Piccirillo, F., Bernardini, F., Filippis, A.d., Coletti, F., Mangiacapra, F., et al. (2022). Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(13), 7261 [10.3390/ijms23137261].
Nusca, A; Piccirillo, F; Bernardini, F; Filippis, Ad; Coletti, F; Mangiacapra, F; Ricottini, E; Melfi, R; Gallo, P; Cammalleri, V; Napoli, N; Ussia, Gp; Grigioni, F
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/304915
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact